Loading...
•
Jun 30
OrthoPediatrics Q2 2025 Earnings Report
OrthoPediatrics reported its second quarter 2025 financial results, exceeding $60 million in revenue for the first time and increasing adjusted EBITDA by 58% year-over-year.
Key Takeaways
OrthoPediatrics delivered a strong second quarter in 2025, achieving record-high total revenue of $61.1 million, a 16% increase year-over-year, driven by robust growth in Scoliosis and Trauma & Deformity segments. The company also significantly improved its Adjusted EBITDA by 58% to $4.1 million and reduced its non-GAAP diluted loss per share. This performance led to an increase in full-year 2025 revenue guidance.
Total revenue reached a record $61.1 million in Q2 2025, marking a 16% increase from Q2 2024.
Adjusted EBITDA grew by 58% to $4.1 million in Q2 2025, up from $2.6 million in Q2 2024.
Non-GAAP diluted loss per share improved to ($0.11) in Q2 2025, compared to ($0.23) in Q2 2024.
Full-year 2025 revenue guidance was increased to a range of $237.0 million to $242.0 million.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Revenue by Segment
Trauma & Deformity Revenue
CapyFin.comScoliosis Revenue
CapyFin.comSports Medicine/Other Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
OrthoPediatrics increased its full-year 2025 revenue guidance and reiterated its annual set deployment and adjusted EBITDA targets, expressing confidence in continued growth and achieving positive free cash flow.
Positive Outlook
- Increased full year 2025 revenue guidance to a range of $237.0 million to $242.0 million.
- Revenue guidance represents growth of 16% to 18% compared to prior year.
- Reiterated annual set deployment to be $15.0 million.
- Reiterated $15.0 million to $17.0 million of adjusted EBITDA for the full year 2025.
- On track to generate positive free cash flow by the fourth quarter of 2025, setting the stage for full-year free cash flow breakeven in 2026.
Challenges Ahead
- No specific negative forward guidance points were mentioned in the report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income